You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Comparison of clinical data for pneumonia-related characteristics in HAP patients with XDRAB and non-XDRAB

From: Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality

  XDRAB (N = 21) N (%) Non-XDRAB (N = 42) N (%) P-value
Age, ya 77.5 ± 11.6 68.6 ± 18.4 0.023
Gender (M/F), n 17/4 23/19 0.079
APACHE II scorea 21.9 ± 6.8 18.0 ± 4.9 0.011
Related to hospitalizationa 18 (85.7) 30 (71.4) 0.347
 Days of mechanical ventilation before XDRAB (days) 10.5 ± 11.6 5.2 ± 5.8 0.059
 Hospital days before XDRAB (days) 18.3 ± 11.3 12.6 ± 11.2 0.064
 Length of stay in the ICU (days) 30.1 ± 20.0 21.4 ± 21.7 0.127
 Length of stay in the hospital (days) 45.5 ± 28.8 38.5 ± 24.2 0.199
Associated disease, n (%)
 COPD 13 (61.9) 9 (21.4) 0.001
 Diabetes mellitus 2 (9.5) 10 (40.4) 0.307
 Malignancy 2 (9.5) 9 (21.4) 0.411
 Cardiac disease 13 (61.9) 6 (14.2) 0.000
 Renal disease 5 (23.8) 2 (4.7) 0.065
 Neurological disease 8 (38.0) 22 (52.3) 0.422
Device, n (%)
 Urinary catheter 21 (100.0) 36 (85.7) 0.172
 Nasogastric tube 21 (100.0) 36 (85.7) 0.172
 Mechanical ventilation 16 (76.1) 31 (73.8) 1.000
Drug usage, n (%)
 Glucocorticoids 10 (47.6) 18 (42.8) 0.720
 PPIs 14 (66.7) 32 (76.1) 0.422
Antimicrobial n (%)
 Cephalosporin    
  Second generation 3 (14.2) 5 (11.9) 1.000
  Third generation 7 (33.3) 18 (42.8) 0.649
 β-lactamase inhibitor 20 (95.2) 31 (73.8) 0.089
 Quinolone 13 (61.9) 19 (45.2) 0.327
 Aminoglycoside 2 (9.5) 4 (9.5) 1.000
 Carbapenem 11 (52.3) 11 (26.1) 0.040
 Antimicrobial Combination therapy, n (%) 11 (52.3) 19 (45.2) 0.593
Mortality, n (%) 9 (42.8) 15 (35.7) 0.582
  1. aValues are presented as the mean ± standard deviation; malignancy includes haematological malignancies and solid tumours; cardiac disease includes coronary artery disease, hypertensive heart disease, valvular disease and cardiomyopathy; renal disease includes chronic renal failure; neurological disease includes cerebral haemorrhage and cerebral infarction; PPIs proton pump inhibitor drugs